Paid Clinical Trials Maine
Discover 216 paid clinical trials in Maine. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaThoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Sponsor:
Children's Oncology Group
Location:
Code:
NCT05235165
Conditions
Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma
Eligibility Criteria
Sex: All
Age: 0 - 50
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Questionnaire Administration
Thoracoscopy
Thoracotomy
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Sacituzumab tirumotecan
Capecitabine
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaFixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Sponsor:
Inhye Ahn
Location:
Code:
NCT06333262
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pirtobrutinib
Obinutuzumab
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06291376
Conditions
Immunoglobulin A Nephropathy
IgAN
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ravulizumab
Placebo
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Sponsor:
AbbVie
Location:
Code:
NCT05814627
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Adalimumab
Upadacitinib Matching Placebo
Adalimumab Matching Placebo
Micronutrients as Adjunctive Treatment for Bipolar DisorderMicronutrients as Adjunctive Treatment for Bipolar Disorder
Sponsor:
Eastern Maine Medical Center
Location:
Code:
NCT03541031
Conditions
Bipolar Disorder
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Micronutrient & Fish oil
Olive oil & Safflower oil
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT06116682
Conditions
Lung Non-Small Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Amivantamab
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast CancerOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Sponsor:
Stemline Therapeutics, Inc.
Location:
Code:
NCT05563220
Conditions
Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Elacestrant
Alpelisib
Everolimus
Ribociclib
Palbociclib
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06077760
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
V940
Pembrolizumab
Placebo
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Sponsor:
Karyopharm Therapeutics Inc
Location:
Code:
NCT05611931
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Matching Placebo for selinexor